D Policy

WELLINGTON, N.Z.—There are prospects for a major change in science and technology policy in New Zealand following the release of a comprehensive and plain-speaking report. The report, completed in December but just now being discussed, said the "key to prosperity" lies in moving the nation rapidly toward a Scandanavian-type economy based on science and technology, (e.g. small, high-value, high tech products in medicine, electronics and biotechnology). The report is named after Sir David Be

Written byPeter Pockley
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The report is named after Sir David Beattie, a respected former judge and governor-general, whose seven-member committee was asked last year by Bob Tizard, the Minister for Science and Technology, to provide a national blueprint for R&D. The issue is an urgent one because New Zealand is seeking a successful financial niche following a drastic drop in its traditional export income from farm produce.

The committee is pressing for: a doubling in per capita R&D expenditure over the next seven years, from a current base of $250 million; much higher visibility for science, with a more powerful senior minister for science and technology, a cabinet committee, an external advisory board, and three research councils to disburse funds on a competitive basis; a 150 percent tax deductibility to encourage in-house R&D by industry (specifically, to catch up with a similar recent Australian scheme); increased support for universities and for basic research; ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies